TY  - JOUR
AU  - Calleja Conde, Javier
AU  - Echeverry Alzate, Víctor
AU  - Giné Domínguez, Elena
AU  - Buhler, Kora Mareen Katharina
AU  - Nadal, Roser
AU  - Maldonado, Rafael
AU  - Rodríguez De Fonseca, Fernando Antonio
AU  - Gual, Antoni
AU  - López Moreno, José Antonio
PY  - 2016
DO  - 10.1111/bph.13526
SN  - 0007-1188
UR  - https://hdl.handle.net/20.500.14352/97777
T2  - British Journal of Pharmacology
AB  - Background and PurposeThe opioid antagonist nalmefene (selincro®) was approved for alcohol-related disorders by the European Medicines Agency in 2013. However, there have been no studies regarding the effectiveness of nalmefene when alcohol is used in...
LA  - eng
M2  - 2490
PB  - British Pharmacological Society
TI  - Nalmefene is effective at reducing alcohol seeking, treating alcohol-cocaine interactions and reducing alcohol-induced histone deacetylases gene expression in blood
TY  - journal article
ER  -